Why Is PRECIGEN INC (PGEN) Stock Moving Today?

PGEN stock is moving higher by 12.1% as of 10:30 AM ET, driven by the company's recent second-quarter financial results and strategic developments. Precigen reported a 145% year-over-year increase in PAPZIMEOS revenue to $53.1 million, achieving profitability for the first time. The company also secured seven-year FDA exclusivity for PAPZIMEOS, expanding its market reach and reinforcing its competitive position.

What Happened

Precigen’s Q2 2026 earnings report highlighted a significant acceleration in PAPZIMEOS revenue, which more than doubled from the prior quarter. GAAP earnings per share of $0.05 exceeded estimates by $0.06, while total revenue of $54.98 million beat expectations by $27.15 million. The company disclosed these results in a Form 8-K filing on August 4, 2026, and reiterated the performance in a press release through PR Newswire. Management emphasized that PAPZIMEOS gross margin is expected to stabilize in the high 80% to low 90% range, with a target of achieving cash flow breakeven by the end of 2026. The stock opened with a 12.1% gap up from the prior close, reflecting strong investor reaction to the news.

What The Data Shows

The stock has traded in a wide 52-week range of $1.70 to $6.80, and the recent intraday move reflects a sharp reversal. Volume has reached 4.7 million shares, matching the 3-month daily average. Unusual options activity has also been noted, with a notable call premium of $281,000 and no put activity. Meanwhile, insider transactions over the last 90 days show 10 sell filings totaling $5.4 million, with recent sales by the COO and CFO.

What To Watch

Precigen has no upcoming earnings date in the near term, but investors should monitor the breadth of coverage and analyst commentary, particularly as the company continues to expand its commercial reach and solidify its market position.